-
-
Call more information
660-596-2224 -
The US Food and Drug Administration (FDA) has approved an abuse-deterrent extended-release formulation of oxycodone (Targiniq ER, Purdue Pharma LP), a combination of oxycodone hydrochloride and naloxone hydrochloride, the agency announced today. The new formulation is approved to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are […]
Read MoreSlower growth in U.S. healthcare spending and expected savings from Obamacare are shoring up the funding outlook for the federal Medicare program that covers the hospital bills of the elderly, trustees of the program said on Monday. The program’s trust fund for hospital care will run out of money in 2030, four years later than […]
Read MoreAnesthesia providers had high numbers of hand hygiene (HH) opportunities in the operating room per hour, but low levels of HH compliance, according to a new study. Compliance was lowest during the first and last 20-minute periods in the operating room. “Complete compliance with HH practice as recommended by World Health Organization guidelines would have […]
Read MoreThe US Food and Drug Administration (FDA) has approved an abuse-deterrent extended-release formulation of oxycodone (Targiniq ER, Purdue Pharma LP), a combination of oxycodone hydrochloride and naloxone hydrochloride, the agency announced today. The new formulation is approved to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment, for which alternative treatment options are […]
Read MoreStan Xuhui Li, MD, of Hamilton, New Jersey, was a full-time anesthesiologist at a local hospital who had a sideline. On weekends, the 60-year-old Dr. Li saw patients in a pain-management clinic 80 miles away in the Queens borough of New York City. A jury in a New York state court concluded on July 18 […]
Read More